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rates: transmission from infected animals to persons clan-
destinely engaging in ritual slaughter; specifically, an 
Ethiopian Jewish community. Physicians in countries re-
ceiving immigrants should be aware of ceremonial prac-
tices that place patients at risk for zoonoses. The severe 
respiratory manifestations that ensued following aerosol 
exposure to animal blood or secretions suggest that bru-
cellosis with pulmonary involvement after inhalation of 
Brucella-infected aerosols might be more common than 
previously documented.
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To the Editor: The 2014–2015 epidemic of Ebola vi-
rus disease (EVD) in West Africa affected 23,666 persons 
and caused 14,603 deaths (1). The World Health Organiza-
tion (WHO) declared the epidemic a public health emergen-
cy (2). Although Ebola virus is transmitted by unprotected 
physical contact with infected persons, published reports 
about which body fluids are infected or the risk for fomite 
transmission are few (3). For most cases, virus was detected 
by reverse transcription PCR (RT-PCR) of clinical (saliva, 
feces, semen, breast milk, tears, nasal blood, skin swab) and 
environmental specimens (4). Earlier reports of the follow-
up of recovered patients stated that viral RNA was detected 
by RT-PCR for up to 33 days in vaginal, rectal, and con-
junctival swab samples from 1 patient and up to 101 days in 
seminal fluid from 4 patients. Infectious virus was detected 
in 1 seminal fluid sample 82 days after disease onset (4,5).
Attendees at the Eighth Meeting of the WHO Advisory 
Group on the EVD Response (1) discussed potential risk 
factors, including hidden chains of transmission and sexual 
transmission, and determined the following criteria. A coun-
try can declare “interruption of transmission” when 42 days 
have elapsed since the last diagnosis of a case. A country 
can declare that the “outbreak has stopped” when test results 
from the last case are negative twice or after another 90-day 
interval. For determining a cutoff for finally declaring the 
strategy and criteria for elimination, extensive follow-up on 
infectivity of semen in Ebola survivors is needed.
We report follow-up of a man who recovered from 
EVD and was monitored for 165 days after he was declared 
Ebola-free. The 26-year-old man from India returned to 
New Delhi, India, from Liberia on November 10, 2014, with 
a certificate from the government of Liberia stating that he 
was “cured” of Ebola. Because EVD is considered an exotic 
disease in India, he was placed in isolation at the Airport 
Health Organization quarantine center at Indira Gandhi In-
ternational Airport, New Delhi (6). Serum and semen sam-
ples were collected and sent to the National Centre for Dis-
ease Control (NCDC), New Delhi, and the National Institute 
of Virology (NIV), Pune, India. The serum was negative by 
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real-time RT- PCR ([7]; http://www.cdc.gov/vhf/ebola/diag-
nosis/index.htm) and positive (titer 1:400) by IgG ELISA 
(8). However, the semen was positive for Ebola viral RNA 
by real-time RT-PCR. A viral RNA extraction kit (QIAGEN, 
Valencia, CA, USA) was used to extract RNA from samples. 
Real-time RT-PCRs were set up in a Bio-Rad real-time PCR 
machine (Model C1000 Touch CFX96; Hercules, CA, USA) 
by using a SuperScript III Platinum One-Step qRT-PCR kit 
with ROX (Invitrogen, Carlsbad, CA, USA).
As a confirmatory measure, partial nucleoprotein gene 
(1216 nt), partial viral protein (VP) gene (337 nt), and the 
intergenic region near the VP gene along with VP polyA tail 
(383 nt) from the semen sample were amplified by RT-PCR 
(9). These sequences (GenBank accession nos. KT191140–
KT191142) showed 100% similarity with Zaire ebolavirus 
isolate EBOV/DML14077/SLe/WesternUrban/20150630. 
To avoid cross-contamination, we used a γ-inactivated 
Ebola Reston virus strain as a positive control. The RT-
PCRs were set up in a Bio-Rad thermal cycler (C1000) 
by using SuperScript III One-Step RT-PCR System with 
Platinum-Taq-DNA-Polymerase (Invitrogen).
Ebola virus isolation attempts were made from the se-
men sample in VeroE6 cells, Vero CCL81, Pipistrellus bat 
embryo, and BHK-21 cell lines at NIV. No isolate was ob-
tained. Cycle thresholds of 28.5 and 31.5 were observed 
in Vero CCL81 and Vero E6 cells, respectively, in the first 
passage by real time RT-PCR, but no virus or cytopathic 
effect was detected in the subsequent 2 passages (Table).
According to WHO guidelines, the semen sample was 
transported from NCDC to a Biosafety Level 4 laborato-
ry at NIV (for virus isolation). At the time of inoculation 
in cell culture, the sample had been subjected to a single 
freeze–thaw cycle. The sensitive nature of the virus may be 
why Ebola virus was not isolated. PCR positivity alone is 
not sufficient for considering a patient infectious for Ebola; 
however, because EVD is considered an exotic disease in 
India, we depended on real-time RT-PCR–based data for 
establishing EVD positivity.
Follow-up semen samples were positive by real time 
RT-PCR for up to 165 days after the patient was declared 
Ebola-free and were negative thereafter. Cycle thresholds 
of samples tested at NIV were 22.5 on day 45 after being 
declared Ebola-free, 24 on day 64, 34 on day 125, 38 on 
day 141, and 35.0 on day 165 (Table). 
Clear criteria for elimination and declaration of the end 
of an outbreak are needed because any misinterpretation or 
miscommunication among the countries could negatively af-
fect community confidence (10). Although we monitored the 
patient for 165 days, monitoring began ≈10 days after the 
patient had recovered. Ebola viral RNA persistence has been 
documented in a human semen sample for up to 10 months 
after the patient was declared Ebola-free (11). According to 
the data from this study, the current elimination period may 
need to be extended, and further studies on the infectivity of 
semen samples from recovered EVD patients are warranted.
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NCDC‡ NIV§ CPE Ct CPE Ct CPE Ct CPE Ct 
1 45 17 22.5 Vero CCL81 None 28.5  None None  None None  None None 
Vero E6 None 31.5  None None  None None  ND None 
2 64 21 24 Vero CCL81 None None  None None  None None  ND ND 
Vero E6 None 32.5  None None  None None  ND ND 
3¶ 77 22 ND NA NA NA  NA NA  NA NA  NA NA 
4¶ 98 26 ND NA NA NA  NA NA  NA NA  NA NA 
5¶ 111 27 ND NA NA NA  NA NA  NA NA  NA NA 
6 125 30 34 Vero CCL81 None None  None None  ND ND  ND ND 
Vero E6 None None  None None  ND ND  ND ND 
7 141 28 38 Vero CCL81 None None  None None  ND ND  ND ND 
Vero E6 None None  None None  ND ND  ND ND 
8 165 28 35.0 Vero CCL81 None None  None None  ND ND  ND ND 
BHK-21 None None  None None  ND ND  ND ND 
*Ct, cycle threshold; CPE, cytopathic effect; NA, not applicable; NCDC, National Centre for Disease Control, New Delhi, India; ND, not done; NIV, 
National Institute of Virology, Pune, India; RT-PCR, reverse transcription PCR.  
†Primers from http://www.crcf.sn/wp-content/uploads/2014/09/CDC-Ebola-International-Lab.pdf. 
‡Primers from the Centers for Disease Control and Prevention, Atlanta, Georgia, USA. 
§Primers from (7). 
¶Samples received at NCDC only.  
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To the Editor: Mayaro virus (MAYV), a mosquito-
borne alphavirus endemic to South America, causes a self-
limiting febrile arthralgia syndrome closely resembling 
Chikungunya fever (1). MAYV has been detected increas-
ingly as imported infections in international travelers re-
turning to Europe and North America (2–9). Joint pain, 
the most prominent symptom, is often long-lasting (sev-
eral months), sometimes incapacitating (4,6,7,9), and may 
recur (8). Arthralgia develops during the acute phase and 
symmetrically affects the wrists, ankles, and small joints 
of hands and feet. Joint swelling may occur initially, but 
permanent joint damage has not been described (5). The 
clinical disease and diagnostic procedures have been de-
scribed (1–9), but immunologic parameters and their pos-
sible role in the clinical follow-up of patients (i.e., during 
the postacute long-lasting arthralgia period) remain to 
be investigated.
To further our knowledge of MAYV infection, we ana-
lyzed cytokine levels in serum samples from 6 travelers to 
South America who returned to Europe with Mayaro fever 
(MF). Two of the cases occurred during 2014; 4 occurred 
during 2011–2013 (2–5).
The 6 travelers comprised 2 men and 4 women who 
were 20–54 (median 36) years of age (online Technical Ap-
pendix Table, http://wwwnc.cdc.gov/EID/article/22/4/15-
1502-Techapp1.pdf). The 2 most recent cases occurred in 
spring 2014 in a 28-year-old female student and a 54-year-
old male physician. Serologic testing was performed for 
both patients at the Bernhard Nocht Institute and confirmed 
by virus neutralization testing (4).
The student had traveled for 3 weeks in Ecuador, visit-
ing rainforest villages and hiking in the jungle. During her 
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